Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.49 |
| ▸ | GRM6 | O15303 | 1/20 | 0.49 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822594 | 0.83 | SMN1; SMN2 (0.52) | ALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL27790851 | 0.80 | TAAR1 (0.50) | ALDH1A1RIPK1 | |
| SCHEMBL27811910 | 0.80 | FOLH1 (0.44) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL10042378 | 0.79 | RIPK1 (0.52) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL242853 | 0.79 | RIPK1 (0.52) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL8673121 | 0.79 | RIPK1 (0.52) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL5743278 | 0.78 | RIPK1 (0.50) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Phosphoric Acid SCHEMBL27969322 | 0.76 | RIPK1 (0.48) | ALDH1A1RIPK1 | |
| SCHEMBL1716157 | 0.76 | CYSLTR2 (0.50) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL1373545 | 0.76 | GRM3 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094720-A1 | SELECTIVE INHIBITORS OF NEUROTENSIN DEGRADING ENZYMES | Solvay Pharmaceuticals B.V. (NL) | 2009-09-02 | — | — | EP | disclosed |
| US-20080146524-A1 | Selective inhibitors of neurotensin degrading enzymes | SOLVAY PHARMACEUTICALS B.V. | 2008-06-19 | — | — | US | disclosed |
| WO-2008071738-A1 | SELECTIVE INHIBITORS OF NEUROTENSIN DEGRADING ENZYMES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146524-A1 | Selective inhibitors of neurotensin degrading enzymes | COMT, NTSR1, CMA1 | GRM8 2398/4885GRM6 1535/4885GRM7 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.